Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 4
1976 1
1977 2
1978 1
1979 1
1980 1
1981 2
1982 3
1983 6
1984 4
1985 4
1986 3
1987 4
1988 7
1989 8
1990 16
1991 5
1992 18
1993 16
1994 23
1995 12
1996 31
1997 25
1998 32
1999 23
2000 38
2001 34
2002 21
2003 37
2004 47
2005 38
2006 47
2007 50
2008 48
2009 60
2010 72
2011 72
2012 70
2013 75
2014 77
2015 108
2016 110
2017 99
2018 129
2019 119
2020 141
2021 133
2022 108
2023 117
2024 57

Text availability

Article attribute

Article type

Publication date

Search Results

1,867 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Anaplastic (Malignant) Meningioma"
Page 1
Current treatment options for meningioma.
Apra C, Peyre M, Kalamarides M. Apra C, et al. Expert Rev Neurother. 2018 Mar;18(3):241-249. doi: 10.1080/14737175.2018.1429920. Epub 2018 Jan 22. Expert Rev Neurother. 2018. PMID: 29338455 Free article. Review.
With an annual incidence of 5/100,000, meningioma is the most frequent primary tumor of the central nervous system. ...The treatment of recurrent tumors is based on radiotherapy and repeated surgery. Systematic therapies are not effective in general but several clin …
With an annual incidence of 5/100,000, meningioma is the most frequent primary tumor of the central nervous system. ...The treatment …
Meningioma.
Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, Vecht C. Marosi C, et al. Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71. doi: 10.1016/j.critrevonc.2008.01.010. Epub 2008 Mar 14. Crit Rev Oncol Hematol. 2008. PMID: 18342535 Review.
Five-year survival for typical meningiomas exceeds 80%, but is poorer (5-year survival <60%) in malignant and atypical meningiomas. Papillary and haemangiopericytic morphology, large tumour size, high mitotic index, absence of progesterone receptors, deletions and loss …
Five-year survival for typical meningiomas exceeds 80%, but is poorer (5-year survival <60%) in malignant and atypical meningiomas …
High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.
Rogers CL, Won M, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Fogh SE, Youssef E, Deb N, Kwok Y, Robinson CG, Shu HK, Fisher BJ, Panet-Raymond V, McMillan WG, de Groot JF, Zhang P, Mehta MP. Rogers CL, et al. Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):790-799. doi: 10.1016/j.ijrobp.2019.11.028. Epub 2019 Nov 29. Int J Radiat Oncol Biol Phys. 2020. PMID: 31786276 Free PMC article. Clinical Trial.
BACKGROUND: Phase 2 cooperative group meningioma trial assessing the safety and efficacy of risk-adaptive management strategies. ...METHODS AND MATERIALS: High-risk patients were those with a new or recurrent World Health Organization (WHO) grade III meningioma …
BACKGROUND: Phase 2 cooperative group meningioma trial assessing the safety and efficacy of risk-adaptive management strategies. ...M …
Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.
Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Brachman D, Jenrette JM, De Groot J, Bovi JA, Werner-Wasik M, Knisely JPS, Mehta MP. Rogers L, et al. J Neurosurg. 2018 Jul;129(1):35-47. doi: 10.3171/2016.11.JNS161170. Epub 2017 Oct 6. J Neurosurg. 2018. PMID: 28984517 Free PMC article. Clinical Trial.
For the intermediate-risk group (Group 2), eligible patients had either newly diagnosed WHO Grade II meningioma that had been treated with gross-total resection (GTR; Simpson Grades I-III) or recurrent WHO Grade I meningioma with any resection extent. ...Afte …
For the intermediate-risk group (Group 2), eligible patients had either newly diagnosed WHO Grade II meningioma that had been treated …
Parasellar Meningiomas.
Graillon T, Regis J, Barlier A, Brue T, Dufour H, Buchfelder M. Graillon T, et al. Neuroendocrinology. 2020;110(9-10):780-796. doi: 10.1159/000509090. Epub 2020 Jun 3. Neuroendocrinology. 2020. PMID: 32492684 Free article. Review.
Long-term follow-up is required given the frequent incomplete tumor removal and the risk of delayed recurrence. Radiosurgery is relevant for small and well-limited meningiomas or intra-cavernous sinus postoperative residue, whereas radiation therapy and proton beam therapy …
Long-term follow-up is required given the frequent incomplete tumor removal and the risk of delayed recurrence. Radiosurgery is relev …
Clinoidal meningiomas.
Pamir MN, Özduman K. Pamir MN, et al. Handb Clin Neurol. 2020;170:25-35. doi: 10.1016/B978-0-12-822198-3.00025-2. Handb Clin Neurol. 2020. PMID: 32586497 Review.
With increasing size, however, clinoidal meningiomas tend to invade surrounding neurovascular structures including distal carotid branches, which results in poor surgical outcome. Most clinoidal meningioma cases are managed with surgery where the anterior clinoid process i …
With increasing size, however, clinoidal meningiomas tend to invade surrounding neurovascular structures including distal carotid branches, …
Advances in the systemic therapy for recurrent meningiomas and the challenges ahead.
Li Y, Drappatz J. Li Y, et al. Expert Rev Neurother. 2023 Jul-Dec;23(11):995-1004. doi: 10.1080/14737175.2023.2254498. Epub 2023 Sep 11. Expert Rev Neurother. 2023. PMID: 37695700 Review.
INTRODUCTION: Meningiomas represent the most common primary neoplasms of the central nervous system (CNS). 20% present with atypical (WHO grade II) or malignant (grade III) meningiomas, which show aggressive biologic behavior and high recurrence. ...AREAS COVERED: T …
INTRODUCTION: Meningiomas represent the most common primary neoplasms of the central nervous system (CNS). 20% present with atypical (WHO gr …
Biology and Treatment of Meningiomas: A Reappraisal.
McFaline-Figueroa JR, Kaley TJ, Dunn IF, Bi WL. McFaline-Figueroa JR, et al. Hematol Oncol Clin North Am. 2022 Feb;36(1):133-146. doi: 10.1016/j.hoc.2021.09.003. Hematol Oncol Clin North Am. 2022. PMID: 34801160 Review.
Identifying high-risk patients requiring intervention is challenging, but recent insights into meningioma biology provide a useful guide for decision making. Standard of care for recurrent or biologically aggressive tumors consists of surgery and radiation therapy. …
Identifying high-risk patients requiring intervention is challenging, but recent insights into meningioma biology provide a useful gu …
Multimodality Therapy of Patients with Refractory Meningiomas.
Ahmad H, Schiff D. Ahmad H, et al. Curr Treat Options Oncol. 2019 May 9;20(6):50. doi: 10.1007/s11864-019-0648-z. Curr Treat Options Oncol. 2019. PMID: 31073797 Review.
Recurrent and refractory meningiomas are a clinical challenge and treatment at the time of recurrence is not well delineated. ...The search for an adjuvant systemic therapy continues and as many of the initially promising approaches have not had reproducible respons …
Recurrent and refractory meningiomas are a clinical challenge and treatment at the time of recurrence is not well delineated. …
Metastatic Atypical and Anaplastic Meningioma: A Case Series and Review of the Literature.
Kessler RA, Garzon-Muvdi T, Yang W, Weingart J, Olivi A, Huang J, Brem H, Lim M. Kessler RA, et al. World Neurosurg. 2017 May;101:47-56. doi: 10.1016/j.wneu.2017.01.070. Epub 2017 Jan 29. World Neurosurg. 2017. PMID: 28143726 Review.
BACKGROUND: Atypical (World Health Organization grade II) and anaplastic (World Health Organization grade III) meningiomas are rare, accounting for less than 5% of all meningiomas. ...RESULTS: We discuss the clinical, radiologic, and histopathologic clinical course of 6 pa …
BACKGROUND: Atypical (World Health Organization grade II) and anaplastic (World Health Organization grade III) meningiomas are rare, …
1,867 results